Mark Sheptoff Financial Planning LLC Has $142,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mark Sheptoff Financial Planning LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 35.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 135 shares of the biopharmaceutical company’s stock after acquiring an additional 35 shares during the period. Mark Sheptoff Financial Planning LLC’s holdings in Regeneron Pharmaceuticals were worth $142,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Global Assets Advisory LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth about $339,594,000. Capital International Investors grew its holdings in Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after purchasing an additional 213,038 shares during the last quarter. First Trust Advisors LP raised its position in shares of Regeneron Pharmaceuticals by 115.2% in the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after purchasing an additional 195,902 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after buying an additional 184,561 shares during the last quarter. Finally, TD Asset Management Inc grew its stake in Regeneron Pharmaceuticals by 162.9% in the 1st quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock valued at $259,402,000 after buying an additional 166,998 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, EVP Marion Mccourt sold 1,137 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the sale, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. Insiders sold 10,026 shares of company stock valued at $11,498,705 over the last ninety days. 7.48% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have issued reports on REGN. Argus upped their price target on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Wells Fargo & Company raised their target price on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. raised their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday. Finally, Piper Sandler upped their price objective on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research report on Friday, August 23rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,111.30.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $1,138.81 on Thursday. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The firm has a market cap of $125.48 billion, a PE ratio of 33.64, a price-to-earnings-growth ratio of 3.97 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 12 month low of $769.19 and a 12 month high of $1,211.20. The company’s 50-day moving average price is $1,129.45 and its two-hundred day moving average price is $1,029.70.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the previous year, the business earned $8.79 EPS. Regeneron Pharmaceuticals’s revenue was up 12.3% compared to the same quarter last year. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.